[1]
Liu, Y.; Hu, M. Absorption and metabolism of flavonoids in the caco-2 cell culture model and a perused rat intestinal model. Drug Metab. Dispos., 2002, 30(4), 370-377.
[2]
Chen, J.; Lin, H.; Hu, M. Metabolism of flavonoids via enteric recycling: role of intestinal disposition. J. Pharmacol. Exp. Ther., 2003, 304(3), 1228-1235.
[3]
Wu, B.; Kulkarni, K.; Basu, S.; Zhang, S.; Hu, M. First‐pass metabolism via UDP‐glucuronosyltransferase: a barrier to oral bioavailability of phenolics. J. Pharm. Sci., 2011, 100(9), 3655-3681.
[4]
Gao, S.; Hu, M. Bioavailability challenges associated with development of anti-cancer phenolics. Mini Rev. Med. Chem., 2010, 10(6), 550-567.
[5]
Hu, M.; Chen, J.; Lin, H. Metabolism of flavonoids via enteric recycling: mechanistic studies of disposition of apigenin in the Caco-2 cell culture model. J. Pharmacol. Exp. Ther., 2003, 307(1), 314-321.
[6]
Hu, M.; Amidon, G.L. Passive and carrier‐mediated intestinal absorption components of captopril. J. Pharm. Sci., 1988, 77(12), 1007-1011.
[7]
Chen, J.; Lin, H.; Hu, M. Absorption and metabolism of genistein and its five isoflavone analogs in the human intestinal Caco-2 model. Cancer Chemother. Pharmacol., 2005, 55(2), 159-169.
[8]
Hu, M. Commentary: bioavailability of flavonoids and polyphenols: call to arms. Mol. Pharm., 2007, 4(6), 803-806.
[9]
Hu, M.; Krausz, K.; Chen, J.; Ge, X.; Li, J.; Gelboin, H.L.; Gonzalez, F.J. Identification of CYP1A2 as the main isoform for the phase I hydroxylated metabolism of genistein and a prodrug converting enzyme of methylated isoflavones. Drug Metab. Dispos., 2003, 31(7), 924-931.
[10]
Jeong, E.J.; Liu, X.; Jia, X.; Chen, J.; Hu, M. Coupling of conjugating enzymes and efflux transporters: impact on bioavailability and drug interactions. Curr. Drug Metab., 2005, 6(5), 455-468.
